MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors

Cancer Lett. 1996 Apr 19;102(1-2):7-16. doi: 10.1016/0304-3835(96)04143-2.

Abstract

Clinical drug resistance poses a major problem in the successful treatment of ovarian cancer. Two genes, MDR1 and MRP, have been found to play a role in the multidrug resistance phenotype of a number of human tumors. Using a sensitive semiquantitative PCR assay we examined 53 primary untreated ovarian tumors for expression of both MDR1 and MRP genes. Approximately one-third of the tumors expressed MDR1 while all the tumors expressed varying levels of the MRP gene.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / biosynthesis
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • ATP-Binding Cassette Transporters / biosynthesis*
  • ATP-Binding Cassette Transporters / genetics
  • Drug Resistance, Multiple*
  • Drug Resistance, Neoplasm
  • Female
  • Gene Expression
  • Humans
  • Multidrug Resistance-Associated Proteins
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / metabolism*
  • Polymerase Chain Reaction
  • Prognosis
  • RNA, Neoplasm / analysis
  • RNA, Neoplasm / genetics

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • ATP-Binding Cassette Transporters
  • Multidrug Resistance-Associated Proteins
  • RNA, Neoplasm